Dark circles, hollowing, fine lines and puffiness can look similar, but they often have different causes. A thoughtful assessment matters more than choosing a trending injectable.
Image note: The accompanying visual is an AI-generated illustration, not a photograph of a real patient, clinician or treatment.
Polynucleotide (PN) and polydeoxyribonucleotide (PDRN) products are being studied for skin-quality applications. The terms are sometimes used together in marketing, but formulations and regulatory status can differ from product to product.
Start with the cause of the concern
The under-eye area can look tired for several reasons, including shadowing from facial structure, visible vessels, pigmentation, changes in skin texture, age-related volume changes or fluid retention. More than one factor may be present. A product aimed at skin quality cannot be assumed to correct every cause of dark circles or hollowing.
What the research says about PN and PDRN
Published studies report potential improvements in measures such as skin texture and elasticity, and early research includes studies around the eyes. However, study sizes, formulations, treatment methods and outcome measures vary. The evidence is still developing; it does not establish PN or PDRN as a guaranteed treatment for dark circles, a replacement for every filler, or a suitable option for every patient.
A 2024 review of polynucleotides in aesthetic medicine summarizes the current literature and its limitations. Results from one formulation should not be assumed to apply to another.
How this differs from hyaluronic-acid filler
Hyaluronic-acid (HA) fillers are used to add or restore volume for specific indications. PN/PDRN products are generally discussed as skin-quality treatments rather than a like-for-like volume replacement. Both approaches require product-specific assessment and carry risks. In the United States, the FDA lists injection in the periorbital area as an unapproved use of dermal fillers; rules and product authorizations differ by country.
Questions to discuss at a consultation
- What is most likely causing the appearance: pigment, shadow, skin texture, volume change or swelling?
- What is the exact product, and what use is it authorized and labelled for in this location?
- What benefits are supported by evidence for this product, and what are its risks and alternatives?
- Who will perform the treatment, and what follow-up and complication plan is in place?
For clinicians, use the product's current instructions for use, local regulations and professional guidance. Do not rely on a generic protocol or a marketing claim to determine suitability.
Further reading
- Lee et al., review of polynucleotides in aesthetic medicine (2024)
- Randomized split-face study of PN and HA for periocular rejuvenation
- U.S. FDA information on dermal fillers and their risks
Explore the SwiftGlamour product catalogue, and verify each product's intended use and regulatory status in your location.
